Stock events for CapsoVision, Inc. (CV)
CapsoVision reported its fourth quarter and full year 2025 financial results, with revenue increasing by 13% in Q4 and 15% for the full year. New accounts grew by 16% in Q4 and 21% for the full year. As of December 31, 2025, CapsoCam Plus had been used by over 161,000 patients. CapsoVision submitted its 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus. CapsoVision completed a $14 million private placement of public equity financing to support product innovation and pipeline advancement. Operating expenses increased due to the development of new CMOS image sensors and clinical trial activities.
Demand Seasonality affecting CapsoVision, Inc.’s stock price
Information regarding the demand seasonality for CapsoVision, Inc. products and services was not found in the provided search results.
Overview of CapsoVision, Inc.’s business
CapsoVision, Inc. is a commercial-stage medical technology company in the healthcare sector, focusing on gastrointestinal diagnostics. They develop advanced imaging and AI-enabled capsule endoscopy solutions for detecting and diagnosing gastrointestinal diseases. Their flagship product is CapsoCam Plus, a wire-free capsule endoscope for visualizing the small bowel. The company also offers CapsoCloud, CapsoView, CapsoAccess, and CapsoRetrieve. CapsoVision is developing CapsoCam Colon with enhanced AI for colon imaging and CapsoCam UGI for potential use in early-stage pancreatic cancer detection. They are also investing in R&D related to next-generation capsule endoscopes and AI-based analytics engines.
CV’s Geographic footprint
CapsoVision, Inc. is headquartered in Saratoga, California, United States.
CV Corporate Image Assessment
CapsoVision aims to develop advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis. The company emphasizes its AI competency and growing image data for training AI models. Its cloud-based architecture eliminates the need for on-site servers, reducing costs and IT maintenance. The submission of its 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus, the expansion of CapsoCam Plus adoption, and the completion of a $14 million private placement contribute to its reputation.
Ownership
Information regarding major institutional and individual owners of CapsoVision, Inc. was not found in the provided search results.
Ask Our Expert AI Analyst
Price Chart
$6.46
